/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Celldex Therapeutics, Inc.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$27.65 0.0427(4.27%) CLDX at 04 Dec 2025 04:28 PM Biotechnology
Lowest Today 27.03
Highest Today 28.45
Today’s Open 27.03
Prev. Close 26.67
52 Week High 29.05
52 Week Low 14.40
Day’s Range: Low 27.03 High 28.45
52-Week Range: Low 14.40 High 29.05
1 day return -
1 Week return +3.03
1 month return +16.83
3 month return +22.02
6 month return +41.72
1 year return +4.64
3 year return -24.09
5 year return +41.87
10 year return -

Institutional Holdings

Kynam Capital Management, LP 9.19

BlackRock Inc 8.36

FMR Inc 8.19

Wellington Management Company LLP 7.88

Vanguard Group Inc 5.96

T. Rowe Price Associates, Inc. 5.75

COMMODORE CAPITAL LP 5.20

Bellevue Group AG 4.98

BB Biotech AG Ord 4.63

Point72 Asset Management, L.P. 4.22

State Street Corp 3.62

Vanguard Total Stock Mkt Idx Inv 3.22

Vanguard Health Care Inv 3.19

Deep Track Capital, LP 3.01

Vestal Point Capital LP 2.64

Geode Capital Management, LLC 2.52

iShares Russell 2000 ETF 2.37

Woodline Partners LP 2.26

US Small-Cap Growth II Equity Comp 2.09

Eventide Asset Management, LLC 2.04

Eventide Healthcare & Life Sciences I 2.04

Pictet Asset Manangement SA 1.96

Polar Capital Holdings PLC 1.85

Polar Capital Biotech S Inc 1.84

Novo A/S 1.81

T. Rowe Price New Horizons 1.49

SPDR® S&P Biotech ETF 1.31

UBS Group AG 1.27

Eversept Partners, LLC 1.26

Vanguard Explorer Inv 1.12

Vanguard Institutional Extnd Mkt Idx Tr 1.08

Pictet-Biotech P USD 1.00

Fidelity Small Cap Index 0.99

FIAM Small Cap Core Composite 0.99

T. Rowe Price Health Sciences 0.97

FIAM Small Cap Core CIT Cl B 0.95

iShares Russell 2000 Value ETF 0.87

American Century Small Cap Growth Inv 0.84

American Century U.S. Small Cap Growth 0.84

Fidelity Stock Selector Small Cap 0.78

Market Status

Strong Buy: 10

Buy: 2

Hold: 2

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 1772.21 M

PB Ratio 2.8796

PE Ratio 0.0

Enterprise Value 1142.43 M

Total Assets 792.34 M

Volume 804537

Company Financials

Annual Revenue FY23:4365000 4.4M, FY22:2357000 2.4M, FY21:4651000 4.7M, FY20:7418000 7.4M, FY19:3573000 3.6M

Annual Profit FY23:null 0.0M, FY22:2357000 2.4M, FY21:4651000 4.7M, FY20:7418000 7.4M, FY19:3573000 3.6M

Annual Net worth FY23:-124610000 -124.6M, FY22:-122783000 -122.8M, FY21:-70511000 -70.5M, FY20:-59780000 -59.8M, FY19:-50372000 -50.4M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:730000 0.7M, Q1/2025:695000 0.7M, Q3/2024:3191000 3.2M, Q2/2024:2498000 2.5M

Quarterly Profit Q3/2025:-62931000 -62.9M, Q2/2025:730000 0.7M, Q1/2025:695000 0.7M, Q3/2024:3191000 3.2M, Q2/2024:1701000 1.7M

Quarterly Net worth Q3/2025:-67044000 -67.0M, Q2/2025:-56600000 -56.6M, Q1/2025:-53796000 -53.8M, Q3/2024:-42121000 -42.1M, Q2/2024:-35842000 -35.8M

Fund house & investment objective

Company Information Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.

Organisation Biotechnology

Employees 186

Industry Biotechnology

CEO Mr. Anthony S. Marucci M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow